ADTX:NSD-Aditx Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.39

Change

+0.01 (+0.30)%

Market Cap

USD 3.79M

Volume

3.97M

Avg Analyst Target

USD 6.00 (+76.99%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ADTX Stock Forecast & Price:
Based on the Aditx Therapeutics Inc stock forecasts from 2 analysts, the average analyst target price for Aditx Therapeutics Inc is USD 6.00 over the next 12 months. Aditx Therapeutics Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Aditx Therapeutics Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Aditx Therapeutics Inc’s stock price was USD 3.39. Aditx Therapeutics Inc’s stock price has changed by +27.44% over the past week, +2,101.30% over the past month and -95.99% over the last year.

About Aditx Therapeutics Inc (ADTX:NSD)

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed a ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ADTX

Symbol Name Weight Mer Price(Change) Market Cap
EXH8:F iShares (DE) I - iShares .. 14.30 % 0.46 %

+0.12 (+0.49%)

USD9.69M
EXH8:XETRA iShares (DE) I - iShares .. 14.30 % 0.46 %

+0.59 (+2.50%)

USD9.69M
XESD:F Xtrackers - Spain UCITS E.. 7.92 % 0.30 %

+0.01 (+0.05%)

USD0.05B
XESP:F Xtrackers Spain UCITS ETF.. 7.92 % 0.30 %

+0.01 (+0.05%)

USD0.05B
XESD:XETRA Xtrackers Spain UCITS ETF.. 7.92 % 0.30 %

+0.15 (+0.89%)

USD0.05B
XESP:XETRA Xtrackers Spain UCITS 1C 7.92 % 0.30 %

+0.19 (+0.89%)

USD0.04B
WTIM:F WisdomTree Eurozone Quali.. 5.21 % 0.29 %

-0.01 (-0.08%)

USD0.06B
WTIM:XETRA WisdomTree Eurozone Quali.. 5.21 % 0.29 %

+0.28 (+1.54%)

USD0.05B
WSRD:CA Wealthsimple Developed Ma.. 2.06 % 0.28 %

+0.12 (+0.56%)

USD0.42B
FCIQ:CA Fidelity International Hi.. 1.85 % 0.45 %

+0.21 (+0.78%)

USD0.36B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -87.35% 7% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.35% 7% F 6% F
Trailing 12 Months  
Capital Gain -95.84% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.84% 3% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -36.92% 8% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.92% 8% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 40.07% 57% F 37% F
Risk Adjusted Return -92.14% 10% F 3% F
Market Capitalization 3.79M 1% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 90% A- 99% A+
Price/Book Ratio 2.62 35% F 29% F
Price / Cash Flow Ratio -0.17 10% F 42% F
EV/EBITDA -0.16 39% F 52% F
Management Effectiveness  
Return on Equity -1,248.43% 3% F 2% F
Return on Invested Capital -371.26% 4% F 8% F
Return on Assets -128.80% 3% F 1% F
Debt to Equity Ratio 1.08% 82% B- 83% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.36 71% C- 64% D
Short Percent 3.74% 48% F 38% F
Beta 1.27 43% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.